Home
|
Contact us
|
Disclaimer
Corporate Overview
Management
Board of Directors
Contact us
Business Ethics
Product pipeline
Alzheimer's disease
Bipolar disorder
Diabetes and obesity
Inflammatory diseases
Current partnership
In/Out-licensing opportunity
Agitation/aggression in AD
Bipolar disorder
Diabetes and obesity
Cognition/function in AD
Stock quote
Financial reports
Analyst coverage
Request information
Subscribe to e-mail alert
Press release 2013
Press release archive
Webcast and presentation
DRUG CANDIDATES
ELND005 - Alzheimer's disease
ELND005 - Bipolar disorder
TT401 - Diabetes and obesity
TT301/302 - Inflammation
PRODUCT PIPELINE
View Transition's product pipeline
LATEST NEWS
Transition Therapeutics Announces Third Quarter Fiscal 2013 Financial Results
Link to Conference Call on 2013 Third Quarter Results
© 2012 Transition Therapeutics Inc.
